Cereno Scientific (4A1) Stock Overview

A clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. More details

4A1 fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	1/6
Dividends	0/6

Risk Analysis

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 28% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the German market

Currently unprofitable and not forecast to become profitable over the next 3 years

4A1 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW479,582 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

479,582 investors already sharing narratives

View all narratives

Cereno Scientific AB (publ) Competitors

Price History & Performance

Summary of share price highs, lows and changes for Cereno Scientific
Historical stock prices
Current Share Price	SEK 0.45
52 Week High	SEK 0.91
52 Week Low	SEK 0.39
Beta	-0.37
1 Month Change	-15.93%
3 Month Change	-16.85%
1 Year Change	-44.53%
3 Year Change	920.22%
5 Year Change	0.33%
Change since IPO	59.86%

Recent updates

Shareholder Returns

	4A1	DE Biotechs	DE Market
7D	11.3%	-0.1%	0.1%
1Y	-44.5%	11.4%	-0.5%

Return vs Industry: 4A1 underperformed the German Biotechs industry which returned 13.3% over the past year.

Return vs Market: 4A1 underperformed the German Market which returned 0.3% over the past year.

Price Volatility

Is 4A1's price volatile compared to industry and market?
4A1 volatility
4A1 Average Weekly Movement	16.9%
Biotechs Industry Average Movement	7.7%
Market Average Movement	5.3%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	2.7%

Stable Share Price: 4A1's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 4A1's weekly volatility has increased from 12% to 17% over the past year.

About the Company

Founded	Employees	CEO	Website
2012	10	Sten Sorensen	www.cerenoscientific.com

Cereno Scientific AB (publ), a clinical stage biotechnology company, develops therapeutics to treat cardiovascular and pulmonary diseases in Sweden. The company’s lead drug candidate is CS1, a HDACi, proprietary reformulation of VPA that is in phase II clinical trial for the treatment of rare disease pulmonary arterial hypertension, as well as a histone deacetylase (HDAC) inhibitor that acts as an epigenetic modulator for pathological vascular remodeling, fibrotic tissue remodeling, inflammatory processes, pulmonary arterial pressure, thrombotic mechanisms. Its drugs portfolio includes CS014, an epigenetic modulator that is in phase I clinical trial for the treatment of cardiovascular, pulmonary diseases, pulmonary hypertension, and idiopathic pulmonary fibrosis; and preclinical drug candidates comprises CS585, a selective prostacyclin (IP) receptor agonist for the treatment of rare thrombotic diseases.

Cereno Scientific AB (publ) Fundamentals Summary

How do Cereno Scientific's earnings and revenue compare to its market cap?
4A1 fundamental statistics
Market cap	€136.32m
Earnings (TTM)	-€10.97m
Revenue (TTM)	€6.04m

22.6x

P/S Ratio

-12.4x

P/E Ratio

Is 4A1 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
4A1 income statement (TTM)
Revenue	SEK 66.82m
Cost of Revenue	SEK 0
Gross Profit	SEK 66.82m
Other Expenses	SEK 188.17m
Earnings	-SEK 121.35m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

Aug 26, 2026

Earnings per share (EPS)	-0.39
Gross Margin	100.00%
Net Profit Margin	-181.61%
Debt/Equity Ratio	76.4%

How did 4A1 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/22 20:46
End of Day Share Price	2026/07/22 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cereno Scientific AB (publ) is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jyoti Prakash	Edison Investment Research
Oscar Haffen Lamm	Stifel, Equities Research

Cereno Scientific (4A1) Stock Overview

Risk Analysis

Join community and earn perks

Cereno Scientific AB (publ) Competitors

Heidelberg Pharma

Genetic Analysis

Formycon

Dextech Medical

Price History & Performance

Recent News & Updates

New major risk - Share price stability

First quarter 2026 earnings released

No independent directors

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2026

Cereno Scientific Reports Favorable Safety and Tolerability After 12 Months of Cs1 Treatment in Pah from the Expanded Access Program

Cereno Scientific AB Receives Approval to Initiate Fda-Aligned Phase I Pharmacokinetic Study of Cs014 Supporting Phase Ii Development in Ph-Ild

Recent updates

New major risk - Share price stability

First quarter 2026 earnings released

No independent directors

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2026

Cereno Scientific Reports Favorable Safety and Tolerability After 12 Months of Cs1 Treatment in Pah from the Expanded Access Program

Cereno Scientific AB Receives Approval to Initiate Fda-Aligned Phase I Pharmacokinetic Study of Cs014 Supporting Phase Ii Development in Ph-Ild

Cereno Scientific Provides Update on Expanded Access Program for CS1

Cereno Scientific AB (publ) Broadens Development Focus for CS014 to Pulmonary Hypertension Associated with Interstitial Lung Disease

Cereno Scientific Announces First Peer-Reviewed Publication on HDAC Inhibitor CS014: Antithrombotic Efficacy

Cereno Scientific AB (publ) to Report Fiscal Year 2025 Final Results between Apr 13, 2026 and Apr 17, 2026

Cereno Scientific AB Receives FDA Clearance to Initiate Global Phase IIb Trial of CS1 in Pulmonary Arterial Hypertension (PAH)

Cereno Scientific AB to Present New Data of CS014 at the Pharmacology 2025 on December 15-18

Cereno Scientific AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 99.999942 million.

Cereno Scientific Submits Phase IIb Trial Protocol for CS1 in Pulmonary Arterial Hypertension to the U.S. FDA

Cereno Scientific Receives Fda Fast Track Designation for Cs1 in Rare Disease Pulmonary Arterial Hypertension (Pah)

Cereno Scientific AB Announces Positive Topline Results from Phase I Trial of CS014

Cereno Scientific Selects Top-Tier Global Contract Research Organization for Phase IIb Trial of CS1 in the Rare Disease Pul Arterial Hypertension

Cereno Scientific AB (publ) Announces Top-Line Results of the CS014 Phase I Trial to Be Announces Mid-July 2025

Cereno Scientific AB (Publ) Announces Board Elections

Cereno Scientific AB Receives Approval from FDA on Plans for Phase IIb Trial of CS1 in Rare Disease Pulmonary Arterial Hypertension (PAH)

Cereno Scientific AB Presents Cs1's Phase Iia Trial Results At the 5Th Baltic Pulmonary Hypertension Conference 2025

Cereno Scientific AB Completes Successful FDA Meeting Discussing Further Clinical Development of Drug Candidate CS1 in Rare Disease PAH

Cereno Scientific Reports That Its Phase I Trial of CS014 Has Been Concludes and Confirms That Top-Line Results Are Anticipated in June 2025

Cereno Scientific Extends Patent Protection for Drug Candidate CS1 in the US and Has Filed to Extend Market Exclusivity to 2045

Cereno Scientific Secures FDA Meeting to Advance Its Development of CS1 for the Treatment of Rare Disease PAH

Cereno Scientific Announces Additional Phase IIa Trial Data with Drug Candidate CS1 in Pulmonary Ar Arterial Hy Hypertension (PAH) Following the Clinical Study Report Completion

Cereno Scientific to Evaluate CS1 with Advanced Imaging Technology

Cereno Scientific Submits Type C Meeting Request with FDA for Phase II Drug Candidate CS1 in Preparation for Further Clinical Development

Cereno Scientific AB Receives Approval to Initiate Sub- Study of the CS1 EAP Using Fluidda's Innovative Imaging Technology to Obtains Insights on the Long-Term Disease-Modifying Potential of CS1 in PAH

Cereno Scientific's HDAC Inhibitor CS014 Advances

Cereno Scientific's HDACi CS014 Successfully Completed Part One of Its Phase I Trial Evaluating the Safety Profile with A Single Ascending Dose (Sad) Study

Cereno Scientific Enters 9 Additional Patients in its Expanded Access Program with CS1 Providing More Long-Term Safety and Efficacy Data in Rare Disease PAH

Cereno Scientific Announces Initiation of Multiple Ascending Dose (MAD) Part of Phase I Trial of the Novel HDAC Inhibitor CS014

Cereno Scientific AB (publ) to Report Q2, 2025 Results on Aug 27, 2025

Cereno Scientific AB (publ) Selects Rare Disease Idiopathic Pulmonary Fibrosis as the Initial Target Indication for Novel HDACi CS014

Cereno Scientific AB (publ) Announces New Preclinical Data Demonstrates Dose Dependent Positive Impact on Reversal of Pulmonary Vascular Remodeling

Cereno Scientific AB Announces Changes in the Nomination Committee's Composition for the Annual General Meeting 2025

No independent directors

Cereno Scientific AB Announces New Preclinical Data for Cereno Scientific's Novel IP Receptor Agonist CS585 Presented at ESC Congress 2024

Cereno Scientific Receives Orphan Medicinal Product Designation in the Eu for Cs1 in Rare Disease Pulmonary Arterial Hypertension

Cereno Scientific AB (publ), Annual General Meeting, Jun 17, 2025

Cereno Scientific Expands Patent Protection for PAH Drug Candidate CS1's Third Patent Family in Brazil

First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014

Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014

Cereno Scientific AB (publ) to Report Q1, 2025 Results on May 22, 2025

Cereno Scientific AB (Publ) Announces Nomination Committee Appointments Ahead of Annual General Meeting 2025

Cereno Scientific AB (publ), Annual General Meeting, Apr 16, 2024

Cereno Scientific AB (Publ) Approves Election of New Directors

Cereno Scientific AB Submits Clinical Trial Application (CTA) for First-In-Human Phase I Study with Novel Epigenetic HDACi Drug Candidate CS014

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Announces A Study Protocol Presented for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Appoints Don De Bethizy as Board of Directors

Cereno Scientific Publishes Update and Study Protocol for the FDA Approved Expanded Access Program for CS1 in PAH

Cereno Scientific Reports One New Patient Enrolled, One Additional Patient Randomized, and One Additional Patient Completed in the Phase II Study of CS1 in PAH

Full year 2023 earnings released: kr0.21 loss per share (vs kr0.20 loss in FY 2022)

Cereno Scientific Reports Progress of Expanded Access Program and Announces Timeline Adjustment in the Phase II Study of CS1 in PAH

New minor risk - Market cap size

Cereno Scientific AB Appoints Rahul Agrawal as Chief Medical Officer and Head of R&D

Cereno Scientific AB (publ) Appoints Megha Ranjan as Project Director to Strengthen Business Capabilities

Cereno Scientific AB Appoints Julia Fransson as Director of Business Development

Cereno Scientific Receives Expanded Access by the FDA to Drug Candidate CS1 for Rare Disease Pulmonary Arial Hypertension

Cereno Scientific Strengthens R&D with Recruitment of Tatiane Abreu Dall'Agnol as Medical Director

Cereno Scientific AB Confirms New Clinic Activated in the Phase II Study of Drug Candidate CS1 in Rare Disease PAH